Association between chronic hepatitis B infection and COVID-19 outcomes: A Korean nationwide cohort study.

Seong Hee KangDong-Hyuk ChoJimi ChoiSoon Koo BaikJun Gyo GwonMoon-Young Kim

Published in: PloS one (2021)

Underlying CHB and antiviral agents including tenofovir decreased susceptibility to SARS-CoV-2 infection. HBV coinfection did not increase the risk of disease severity or lead to a worse prognosis in COVID-19.

Keyphrases

coronavirus disease
sars cov
hepatitis b virus
respiratory syndrome coronavirus
liver failure
type diabetes